OXYBUTYNIN Drug Patent Profile
✉ Email this page to a colleague
When do Oxybutynin patents expire, and when can generic versions of Oxybutynin launch?
Oxybutynin is a drug marketed by Barr Labs Div Teva, Chartwell Rx, Lannett Co Inc, Pharm Assoc, Pharmobedient Cnsltg, Accord Hlthcare, Ajanta Pharma Ltd, Amneal Pharms, Bionpharma, Impax Pharms, Mylan, Mylan Pharms Inc, Osmotica Pharm Us, Rubicon, Unique, Zydus Pharms, Abhai Llc, Avet Lifesciences, Beximco Pharms Usa, Eywa, Leading, Novast Labs, Novitium Pharma, Quantum Pharmics, Rising, Strides Pharma, Teva Pharms Usa, Tulex Pharms Inc, Upsher Smith Labs, Usl Pharma, and Watson Labs. and is included in thirty-five NDAs.
The generic ingredient in OXYBUTYNIN is oxybutynin chloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxybutynin
A generic version of OXYBUTYNIN was approved as oxybutynin chloride by TEVA PHARMS USA on November 14th, 1988.
Summary for OXYBUTYNIN
Recent Clinical Trials for OXYBUTYNIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 3 |
Benha University | N/A |
Science Valley Research Institute | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for OXYBUTYNIN
Paragraph IV (Patent) Challenges for OXYBUTYNIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OXYTROL | Transdermal System Extended-release | oxybutynin | 3.9 mg/24 hrs | 021351 | 1 | 2008-08-19 |
US Patents and Regulatory Information for OXYBUTYNIN
EU/EMA Drug Approvals for OXYBUTYNIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Teva B.V. | Kentera (previously Oxybutynin Nicobrand) | oxybutynin | EMEA/H/C/000532 Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. |
Authorised | no | no | no | 2004-06-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |